Key points are not available for this paper at this time.
Patients who stopped mepolizumab had an increase in exacerbations and reduced asthma control versus those who continued.
Moore et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: